Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 5/20 | 0.49 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14304888 | 0.83 | ABCB1 (0.51) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL567436 | 0.83 | ABCB1 (0.51) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL7000046 | 0.81 | CTSK (0.57) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL2300007 | 0.81 | CTSK (0.57) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL16272898 | 0.81 | CTSK (0.57) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL29789557 | 0.81 | ABCB1 (0.49) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL2497060 | 0.81 | CTSK (0.57) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL7417025 | 0.81 | ABCB1 (0.49) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL9391793 | 0.81 | CTSL (0.49) | CTSBCTSKCTSSCTSLABCB1 | |
| SCHEMBL1014662 | 0.80 | CTSB (0.44) | CTSBCTSKCTSSCTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2004-09-16 | — | — | US | disclosed |
| EP-0936912-B1 | INHIBITORS OF CYSTEINE PROTEASE | SMITHKLINE BEECHAM CORP (US) | 2004-02-11 | — | — | EP | disclosed |
| US-20020128476-A1 | Inhibitors of cysteine protease | SMITHKLINE BEECHAM CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180927-A1 | Inhibitors of cysteine protease | CTSK, CTSZ, CTSS | CTSB 5/4885CTSK 1/4885CTSS 3/4885 |
| US-20020128476-A1 | Inhibitors of cysteine protease | CTRC, RCE1, CTRL | CTSB 60/4885CTSK 100/4885CTSS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.